ABSTRACT
Psoriasis is a chronic skin disease affecting approximately 2% of the Caucasian population (1) . Chronic plaque psoriasis typically has raised red or white scaly skin lesions with a thickened epidermis, a consequence of keratinocyte (KC) 2 hyperproliferation. The clinical and histological features of the disease are well characterized but the cell and molecular mechanisms involved in the pathogenesis of psoriasis are not yet fully understood. Psoriatic plaques are highly inflammatory lesions with an intense epidermal mononuclear infiltrate of predominately CD8 ϩ T cells (2) . These infiltrating T cells secrete many cytokines, such as tumor necrosis factor-␣, interleukin-6, interleukin-8, and gamma interferon (␥-IFN) (3) , that, in addition to the epidermal-derived cytokines, create an intense inflammatory reaction. The reciprocal activation of CD8 ϩ T cells and KC in this cytokine-rich milieu is a crucial component of the immunopathology of this disease phenotype.
The factors involved in triggering and maintaining the chronic plaque of psoriasis remain undetermined, since no adequate animal or in vitro model exists with which to test them directly. Current therapies available for psoriasis reduce the symptoms of the disease, which often recurs once treatment ceases. An understanding of mechanisms underlying psoriasis immunopathogenesis is therefore of great importance for the development of more effective and specific treatments.
Epidermal proliferation persists in psoriatic plaques despite the presence of ␥-IFN (4), a potent antiproliferative cytokine and inducer of squamous differentiation (5) , represent an intriguing paradox. This fact, in addition to experimental data indicating that psoriatic KC are less sensitive to the antiproliferative effect of ␥-IFN (6, 7), suggests that there may be a defect in the ␥-IFN signaling pathway.
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ligand binding domain) and a 60 kDa ␤ chain necessary for signal transduction (8) . Neither the ␣ nor ␤ chain of the ␥-IFN receptor (R) have intrinsic tyrosine kinase activity. Therefore, ␥-IFN receptor (␥-IFN R) signaling relies on the activity of JAK-1 and JAK-2 tyrosine kinases (Janus kinases), which associate with the ␥-IFN R-␣ and -␤ chains, respectively (9) . After oligomerization of the receptor chains, the associated JAK-1 and JAK-2 tyrosine kinases reciprocally activate each other by phosphorylation.
An immediate event after ligand binding and receptor complex oligomerization is the recruitment of signal transducer and activator of transcription (STAT-1␣) to phosphorylated tyrosine-440 on the ␥-IFN receptor ␣ chain (10) . This recruitment results in the phosphorylation of STAT-1␣ by the JAK kinases and the formation of STAT-1␣ homodimers, which then translocate to the nucleus and bind to the gamma-activated sequence (or GAS sites) in the promoters of ␥-IFN inducible genes (11) .
A critical gene regulated by STAT-1␣ in the ␥-IFN pathway is interferon regulatory factor-1 (IRF-1). IRF-1 is a transcription factor that binds to an interferon-stimulated response element (ISRE) in the promotor of ␥-IFN inducible genes such as intercellular adhesion molecule-1 (12), major histocompatibility complex II (13) , and inducible nitric oxide synthase (14) . The binding of STAT-1␣ to the GAS sites in the IRF-1 promoter is an essential event since STAT-1␣ knockout mice are unable to induce IRF-1 in response to ␥-IFN (15). IRF-1 can, however, be induced directly by other cytokines such as interleukin-6 and leukemia inhibitory factor (16) .
The outcome of the ␥-IFN response is also regulated by IRF-2, a transcription factor with homology to IRF-1. IRF-2 binds to the same DNA motif and represses the activity of IRF-1 (17) . Although both IRF-1 and IRF-2 are constitutively expressed in a variety of cell types, IRF-2 usually predominates over IRF-1 in resting cells (exhibiting 10-fold more binding activity) due to the greater stability of IRF-2 protein (18) . After stimulation with ␥-IFN, the transcription of IRF-1 is induced and its protein levels increase to above the IRF-2 basal level.
IRF-1 has growth inhibitory effects (16) and has been implicated as a tumor suppressor gene (19) because of its role in DNA damage-induced apoptosis (20) . Conversely, IRF-2 has been implicated as having oncogenic activity since overexpression of IRF-2 in fibroblasts caused the loss of growth control in vitro and tumor formation when injected into nude mice (21) . Therefore, the ratio of growth inhibitory IRF-1 to growth-promoting IRF-2 plays a major role in the proliferative capacity of the cell.
Since psoriasis has a genetic component (22) , the nonlesional skin of a psoriatic patient is a valid model with which to investigate differences between psoriatic and normal KC. Nonlesional KC from psoriatic patients have a higher proliferative index, which is maintained on transplantation to nude mice (23) . In addition, nonlesional skin of a psoriatic individual may form a plaque after mechanical injury to the epidermis (the Koebner phenomenon). Therefore, to dissect out the response of psoriatic KC to ␥-IFN from the intense inflammatory reaction within a psoriatic lesion, we used nonlesional skin from psoriatic individuals to generate primary KC cultures in vitro. The use of such established cultures allows investigation of intrinsic differences in the IRF-1 and STAT-1␣ response to ␥-IFN in the KC from psoriatic or an unaffected individual's skin. Here we provide evidence that both IRF-1 and STAT-1␣ activity are reduced in psoriatic KC in vitro.
MATERIALS AND METHODS

Patients
Nine subjects with chronic plaque psoriasis attending the outpatients' clinic, Department of Dermatology, Royal Infirmary, Edinburgh, were recruited. They included two females and seven males aged 21-58. Elliptical biopsies (3 cmϫ1 cm) were taken from nonlesional psoriatic skin at least 6 cm away from active lesions; KC cultures were generated from these biopsies. Normal human KC were generated either from forearm biopsies of unaffected individuals or from skin removed during elective abdominoplasty (Plastic Surgery Unit, St. Johns Hospital, Livingston, W. Lothian, U.K.). Ages of the subjects were 29 -42 years. Additional normal KC lines were generated from the foreskin of infants (Royal Hospital for Sick Children, Edinburgh, U.K.). Foreskin-derived KC showed no difference in transcription factor induction compared with abdominal or forearm-derived KC.
Immunohistochemical staining of skin sections
Elliptical biopsies were obtained from lesional and nonlesional skin of each patient with chronic plaque psoriasis and from healthy volunteers. Biopsies were fixed in 10% buffered formalin, pH 7.4, before embedding in low-temperature paraffin wax and cutting into 3 m sections. Sections were deparaffinized through xylene and graded ethanol to distilled water. Endogenous peroxidase was blocked by immersion in 1% hydrogen peroxide (Sigma, Poole, Dorset, U.K.), followed by permeabilization in boiling 7.14 mM sodium citrate buffer pH 6 (Sigma) in a microwave oven for 2 ϫ 2 min. Sections were loaded onto a Sequenza (Shandon) and blocked in 20% normal swine serum (NSS)/Tris-buffered saline (TBS) pH 7.6. Sections were stained with a 1:300 dilution of polyclonal anti-IRF-1 (Santa Cruz, Autogen, Bioclear, Wilts, U.K.) or a 1:400 polyclonal anti-s100 (Dako U.K. Ltd, Ely, Cambridgeshire, U.K.) in NSS/TBS. Anti-s100 stains melanocytes and Langerhans' cells in the skin, which served as a positive control for immunostaining. Staining was detected with a 1:400 dilution of biotinylated swine anti-rabbit F(abЈ) 2 immunoglobulins (Dako), followed by incubation in avidin/biotin horseradish peroxidase complex (Dako). All incubations were for 30 min at room temperature. Staining was visualized by a 5 min incubation in diaminobenzidine in 0.05 M Tris/HCl buffer pH 7.4 containing 0.01% hydrogen peroxide. Substitution of the primary antibodies with 20% NSS/TBS showed no detectable staining.
Culture of primary human keratinocytes
Subcutaneous fat was removed from the skin, which was chopped into 1 cm squares before digestion in 0.25% trypsin/ EDTA (Gibco Life Technologies, Paisley, U.K.) in salt solution (8 g NaCl, 0.4 g KCl, 1 g glucose/l pH 7) (24) with the addition of 100 IU/ml penicillin, 100 g/ml streptomycin, and 2.5 g/ml Fungizone (Gibco). After digestion with trypsin, the epidermis was scraped off with a scalpel blade, followed by disaggregation of epidermal cells by gentle pipetting. Epidermal cell suspensions were centrifuged at 800 ϫ g for 5 min at 4°C and resuspended in complete keratinocyte serum-free medium (KSFM) (Gibco) supplemented with epidermal growth factor, bovine pituitary extract as supplied by the manufacturer, penicillin, streptomycin, and Fungizone (as above).
Primary KC cultures were initiated by plating out epidermal cell suspensions on a feeder layer of irradiated Swiss 3T3 cells. Six-well tissue culture dishes (Corning Costar, High Wycombe, Bucks., U.K.) were coated with 5 g/cm 2 fibronectin (FBN) (kindly provided by the Scottish National Blood Transfusion Service, Edinburgh, U.K.) in phosphate-buffered saline (PBS) for 20 min at room temperature before aspirating the excess FBN/PBS. Swiss 3T3 were ␥-irradiated (5000 RADS), plated out at 2 ϫ 10 5 per well in FBN-coated plates, and incubated at 37°C/5% CO 2 in a humidified atmosphere for 3 h to adhere. Epidermal cell suspensions were then plated out on top of feeders at 3 ϫ 10 5 cells per well. Cultures received fresh KSFM every 2 or 3 days; KC colonies that came to confluence between 10 and 32 days were passaged to expand numbers in tissue culture flasks without an FBN coating or a 3T3 feeder layer. To compare normal and psoriatic KC at the same passage, KC were frozen after passage 1 and thawed to use at passage 2 in experiments.
Stimulation of primary KC with ␥-IFN
KC were plated out at 1 ϫ 10 5 cells per well of a 6-well dish and ␥-IFN was added between 70 and 90% confluence. Initially, 1000 IU/ml ␥-IFN (R&D Systems, Abingdon, Oxon, U.K.) was added to KC cultures in complete KSFM and cells were harvested at various times after stimulation. Later experiments used 30 IU/ml.
Nuclear extracts
At the time of harvesting, KC cultures were placed on ice and washed with ice-cold PBS. Cells from each well were then scraped off into 1 ml ice-cold PBS, centrifuged at 10,000 ϫ g for 30 s, and lysed in 1 ml buffer A [20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM PMSF, 0.1 mM NaVO4, 0.2% IGEPAL (Sigma, Poole, Dorset, U.K.), 10 % glycerol] (25). Lysates were centrifuged for 2 min at 10,000 ϫ g and the supernatant was discarded before re-centrifugation for 2 min and removal of as much supernatant as possible. The remaining pellet was gently resuspended in 25 l of buffer B [20 mM HEPES pH 7.9, 350 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 20 % glycerol] and incubated for 30 min on ice before centrifugation at 10,000 ϫ g for 10 min. The resulting supernatant was aliquotted and snap frozen in liquid nitrogen before storing at Ϫ70°C. Protein estimations on nuclear extracts were performed by Bradford assay (BioRad Laboratories, Ltd, Herts, U.K.). (26) , and for STAT-1␣ were GACATTTC-CCGTAAATCAT and ATGATTTACGGGAAATGTC (27) (Oswell, Southhampton, U.K.). Oligos were annealed before labeling by heating to 98°C for 10 min and cooling slowly to room temperature. Double-stranded oligos (50 ng) were end-labeled with ␥ 32 P-adenosine triphosphate (ICN Biologicals, Thame, Oxon, U.K.) using T4 polynucleotide kinase (Boehringer-Mannheim, Lewes, E. Sussex, U.K.) and purified using Sephadex G-25 spin columns (Pharmacia, St. Albans, Hert, U.K.). Binding reactions were carried out by incubating 1 g nuclear extract in 20 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.05% IGEPAL, 10 % glycerol, 1 mg/ml nuclease-free BSA (Boehringer), 100 g/ml poly d(I-C) (Boehringer), and 0.25 ng labeled oligos in a volume of 20 l. Competition experiments were carried out by adding unlabeled oligo (either STAT-1 or IRF oligo) to the binding reactions before addition of the labeled probe. Supershift experiments to confirm the identity of the bound protein were performed by the addition of 1 g of specific antibodies to either STAT-1␣ IRF-1 or IRF-2 (Santa Cruz, Autogen Bioclear U.K. Ltd, Wilts, U.K.) to the binding reactions. Binding reactions were incubated at room temperature for 20 min before separating DNA-protein complexes without tracking dye on a 6% polyacrylamide, 0.25X TBE gel at 200 volts for 3-4 h. Gels were fixed in 10% acetic acid before vacuum drying and exposure to autoradiographic film (Kodak Xomat XAR) and a PhosphorImager screen to quantify the binding with a BioRad PhosphorImager and Molecular analyst software (BioRad).
Electrophoretic mobility shift assays
Oligonucleotides (oligos) containing the binding sites for IRF (ISRE) were AAGTGAAAGTGAAAGTGA and TCACTT-TCACTTTCACTT
Statistics
Data was tested for statistically significant differences by the Mann-Whitney test. Values of P Ͻ 0.05 were considered significant.
RESULTS
Immunohistochemical staining for IRF-1 is reduced in psoriatic lesional skin compared with nonlesional or normal skin
The IRF-1 staining pattern was compared in lesional and nonlesional skin from five psoriasis patients and in skin from two normal controls. The normal controls (Fig. 1B) and the nonlesional skin (Fig. 1C) of the psoriatics both showed strong basal cell staining and negligible staining elsewhere. No dermal staining was seen, and staining in the basal layer seemed to be located in KC. In contrast, the psoriatic skin had essentially lost all the basal staining (Fig. 1A) , although in the more severe psoriatic lesions showing epidermal spongiosis, some suprabasal staining was seen.
Induction of IRF-1 activity is reduced in psoriatic KC
The immunohistochemical staining demonstrates that the IRF-1 expression pattern is altered in psori-atic skin, suggesting that this may be an important molecule in psoriatic immunopathology. Since IRF-1 is a major component of the ␥-IFN signaling pathway, it was important to determine whether the DNA binding activity of IRF-1 is altered in nonlesionalpsoriatic KC. IRF-1 DNA binding activity was detected in unstimulated KC ( Fig. 2A) and increased when KC cultures were stimulated with 1000 IU/ml ␥-IFN (shown by the arrow in Fig. 2A) . The induction of binding was observed 1 h after stimulation, increasing to a maximum after 5-8 h in both normal and psoriatic KC. The higher mobility complex in D-G, Fig. 2A ). Experiments to determine the kinetics of IRF-1 activity with 1000 IU/ml ␥-IFN were repeated in different normal and psoriatic KC. The quantification of these experiments is shown in Fig. 2B . The induction of IRF-1 activity is greatly reduced in psoriatic KC compared with normal KC. Further experiments stimulating normal and psoriatic KC with 30 IU/ml ␥-IFN showed reduced activity of IRF-1 in psoriatic KC 5 h after the addition of ␥ -IFN (PϽ0.05, Fig. 3) .
Induction of STAT-1␣ activity is reduced in psoriatic KC
Since IRF-1 had reduced DNA binding activity in psoriatic skin, it is possible that alterations to ␥-IFN signaling may occur earlier in the pathway. STAT-1␣ induction was examined in KC derived from five unaffected individuals and from the nonlesional skin of five patients with chronic plaque psoriasis. One representative experiment is shown in Fig. 4A . Neither normal human KC nor psoriatic KC exhibited STAT-1␣ binding when unstimulated. STAT-1␣ activity was induced 5 min after the addition of 1000 IU/ml ␥-IFN to cultures (Fig. 4A) . The kinetics of STAT-1␣ induction were similar for both normal and psoriatic KC cell lines, with maximal binding activity between 15 and 30 min after the addition of ␥-IFN. Quantification of STAT-1␣ induction was carried out by phosphorimaging and is shown in Fig. 4B . Although STAT-1␣ activity was induced in psoriatic KC after the addition of 1000 IU/ml ␥-IFN, levels of STAT-1␣ binding were significantly reduced compared with normal KC (at 10, 15, 30, and 60 min (PϽ0.04). The identity of the bound protein was shown to be STAT-1␣ by the addition of specific anti-STAT-1␣ antibodies (Santa Cruz), which caused a supershift in the complex (shown by the arrow in lane S1 Fig. 4A ). The STAT-1␣ complex was competed away with cold STAT-1␣ oligos, but not by IRF-1 oligos (data not shown), further confirming that the protein bound to the oligos was STAT-1␣. In dose response experiments, no differential STAT-1␣ induction was observed between normal and psoriatic KC. Both psoriatic and normal KC lines showed significant induction of STAT-1␣ at a dose of 50 IU/ml; maximal induction of STAT-1␣ binding was achieved at 500 IU/ml ␥-IFN (data not shown).
DISCUSSION
The role of the antiproliferative cytokine ␥-IFN in psoriasis is unclear since psoriatic KC continue to proliferate despite high levels of ␥-IFN. One hypothesis is that the ␥-IFN signaling pathway may be defective in psoriatic KC. We provide evidence to support the notion of altered ␥-IFN signaling in psoriatic KC.
Immunohistochemical staining revealed changes in the pattern of IRF-1 expression in lesional psoriatic skin compared with nonlesional or normal skin. IRF-1 expression in normal skin was restricted to the basal layer KC, whereas lesional psoriatic KC showed no basal staining but had either light or no suprabasal expression. This evidence suggests that IRF-1 may play a role in the maintenance of the psoriatic phenotype. The pattern of IRF-1 expression seen here correlates with the expression pattern of ␥-IFN R ␣ chain in one study (28) , suggesting that the areas of functional ␥-IFN signaling in lesional psoriatic skin may be different from those seen in normal skin. These preliminary observations led to the question of whether nonlesional psoriatic KC have altered IRF-1 DNA binding activity compared with normal KC. Using electrophoretic mobility shift assay, we have demonstrated that the DNA binding activity of IRF-1 is reduced in psoriatic KC compared with normal KC. Since IRF-1 has tumor-suppressing activities, reduced activity by this molecule may contribute to the lack of growth control in psoriatic lesions. ␥-IFN induces proliferation in a myeloid cell line that has inhibited IRF-1 expression (29) . It could be speculated that reduced activity of IRF-1 in psoriatic KC may lead to growth-promoting activity by ␥-IFN in vivo.
Since the induction of IRF-1 activity is reduced in nonlesional psoriatic KC, it follows that the induction of STAT-1␣ DNA binding may also be reduced. Indeed we have shown a reduced induction of STAT-1␣ DNA binding in psoriatic KC after 15 min incubation with ␥-IFN. STAT-1␣ activation has been demonstrated to have growth inhibitory effects by mediating expression of p21/WAF1 (30), caspase 1, and apoptosis (31) . Reduced activity of STAT-1␣ by psoriatic KC in response to ␥-IFN suggests that this transcription factor may contribute to the lack of growth control in psoriatic epidermis. STAT-1␣ is present in the cytosol of unstimulated cells and its activity is regulated by phosphorylation. Therefore one explanation for reduced STAT-1␣ activity could be reduced phosphorylation of STAT-1␣ by the JAK kinases. There is some evidence that nitric oxide inhibits JAK2 activity in vitro (32) . Since the synthesis of nitric oxide synthase is increased in psoriatic epidermis (33) , this may be a plausible explanation. Alternatively, reduced STAT-1␣ activity may be a result of decreased surface expression of ␥-IFN receptors in psoriatic KC.
In many cell types, expression of the ␥-IFN ␣ and ␤ receptor chains differs significantly. The ␣ chain is generally constitutively expressed, whereas the ␤ chain is at a very low constitutive level but is regulated by external stimuli (reviewed in ref 8) . Also, there is no correlation between the level of ␣ chain expression and the magnitude of the ␥-IFN-induced response in cells (34) . The only studies investigating the ␥-IFN R expression in psoriatic KC documented the ␣ chain and were also conflicting. Psoriasiform lesions and epidermal proliferation can, however, be induced in the epidermis of psoriasis patients and normal individuals upon local administration of ␥-IFN (36, 37), thus supporting a proinflammatory role for ␥-IFN in psoriatic skin. However, this may reflect the effects of pharmacological rather than physiological doses of ␥-IFN. There is evidence that ␥-IFN given systemically can improve some inflammatory dermatoses, whereas lesional injection increases the disease severity (26) . The presence of locally administered or produced ␥-IFN cannot alone account for the proliferative status of the epidermis. Induction of ␥-IFN was demonstrated in the KC of allergic contact dermatitis patients whose skin had been nickel-challenged, although epidermal hyperproliferation was not evident (38) .
In conclusion, this study has demonstrated that the induction of IRF-1 and STAT-1␣ activity is reduced in nonlesional psoriatic KC. Both IRF-1 and STAT-1␣ have growth inhibitory effects, and thus are implicated in the maintenance of epidermal growth control. Reduced activity of components in the ␥-IFN signaling pathway may play a role in the reduced sensitivity of psoriatic KC to ␥-IFN, both in vitro and in vivo. 
